Levosimendan was first approved for clinical use in 2000, when authorization was granted
by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely …

Sepsis is a major growing global burden and a major challenge to intensive care clinicians,
researchers, guideline committee members and policy makers, because of its high and …

Background Levosimendan is a calcium-sensitizing drug with inotropic and other properties
that may improve outcomes in patients with sepsis. Methods We conducted a double-blind …

Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for
decompensated heart failure (HF) patients with low cardiac output. Accumulated evidence …

Sepsis is one of the most common reasons for critically ill patients to be admitted to an
intensive care unit and, despite advances in overall medical care, it represents a major …

The management of patients with shock is extremely challenging because of the myriad of
possible clinical presentations in cardiogenic shock, septic shock and hypovolemic shock …

Microglia are the largest myeloid cell population in the brain. During injury, disease, or
inflammation, microglia adopt different functional states primarily involved in restoring brain …

Myocardial injury and dysfunction are critical manifestations of sepsis. Previous studies have
reported that liver X receptor (LXR) activation is protective during sepsis. However, whether …

Objective We aim to synthesise up-to-date randomised trials to investigate the effects of
levosimendan on mortality and clinical outcomes in severe sepsis and septic shock …

Purpose Myocardial dysfunction is common in sepsis but optimal treatment strategies are
unclear. The inodilator, levosimendan was suggested as a possible therapy; however, the …